2/12/2024 0 Comments Moderna share priceThat’s the reason why I’m cautiously optimistic about it.” “Although the numbers were limited, it was quite good news because it reached and went over an important hurdle in the development of vaccines,” Fauci said during a CNN town hall. Anthony Fauci, the nation’s top infectious disease expert, cheered the vaccine trial findings. Moderna shares did rebound 2% to $68.60 on Friday after Dr. “It’ll look bad from a PR perspective if Moderna’s stock price starts to fall dramatically after all this trading,” Gordon said. Moderna’s share price fell 10% to $71.67 on Tuesday after health website STAT reported that vaccine experts concluded the company did not release enough information to know how significant the Phase 1 findings are.īy Thursday, Moderna finished at $67.05, down 16% from its Monday close. “It’s not uncommon for insiders to sell shares they own, nor is it bad for them to capitalize on the current stock price,” Gordon said in an email. On May 15, just days before the results were announced, Kim sold 20,000 shares of stock worth $1.3 million.Īndrew Gordon, director of research services at Equilar, said there would only be a “legal issue if they created or modified their 10b5-1 plan while in possession of material insider information.” Kim, the CFO, also made stock sales prior to the vaccine news. The transactions are typically executed automatically, without the insiders taking any action. These plans regulate when and how many shares company insiders, including directors and executives, are allowed to sell. “It’s what a 10b5-1 plan is intended for, assuming the requirements are met.” “On its face, there is nothing wrong with these trades,” Whitehead said. “These transactions are executing automatically pursuant to these trading plans,” the company said.Īlthough the fortuitous timing of the transactions may raise eyebrows, Charles Whitehead, professor at Cornell Law School, said the stock sales did not appear to raise any legal red flags. Moderna said the sales were executed under 10b5-1 trading plans that were established in advance. He immediately sold the shares for $9.77 million, triggering a profit of $8.2 million. The next day, Tal Zaks, Moderna’s chief medical officer, spent $1.5 million to exercise options. In quest for vaccine, US makes 'big bet' on company with unproven technology He then immediately sold them for $19.8 million, creating a profit of $16.8 million. Lorence Kim, Moderna’s chief financial officer, exercised 241,000 options for $3 million on Monday, filings show. The securities transactions were done through automated insider trading plans, known as 10b5-1 plans, that lay out future stock trades at set prices or on set dates. (MRNA)’s market value swelled to $29 billion – even though the company has no marketed products.Īfter spiking to as high as $87 on Monday, Moderna’s stock price has since retreated below $70 as medical experts have debated the importance of the early findings. (MRNA) excited Wall Street before markets opened Monday by announcing encouraging vaccine trial results. Moderna’s chief financial officer and chief medical officer executed options and sold nearly $30 million of shares combined on Monday and Tuesday, SEC filings reviewed by CNN Business show. As ordinary investors piled in, two insiders were quietly heading for the exits. Moderna’s stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |